Aptevo Therapeutics (APVO) Reports Q1, Provides an Update on Mipletamig
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
May 15, 2025 8:06 AM EDT9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials
Mipletamig triplet combination continues to outperform standard doublet benchmark
No cytokine release syndrome observed in the ongoing RAINIER trial: favorable safety profile supports role in frontline AML
Cohort 2 enrollment is complete, and Cohort 3 is now enrolling
Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology Company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today reported financial results for the quarter... More
